Stay updated on Teplizumab in Recent-Onset Type 1 Diabetes Clinical Trial
Sign up to get notified when there's something new on the Teplizumab in Recent-Onset Type 1 Diabetes Clinical Trial page.

Latest updates to the Teplizumab in Recent-Onset Type 1 Diabetes Clinical Trial page
- Check6 days agoChange DetectedThe NIH notice about its terminology transition is no longer shown above the ClinicalTrials.gov 403 error page; the study record remains unavailable.SummaryDifference1%

- Check13 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0. The study record remains unavailable and shows a 403 Forbidden error.SummaryDifference0.2%

- Check20 days agoChange DetectedA banner announces NIH website updates and explains that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during a transition.SummaryDifference1%

- Check27 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changed from v3.7.1 to v3.7.2, while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check34 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1 while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check41 days agoChange DetectedThe record for the teplizumab trial in children and adolescents with newly diagnosed type 1 diabetes is replaced by a 403 Forbidden error page, so its study details and results are no longer displayed.SummaryDifference19%

Stay in the know with updates to Teplizumab in Recent-Onset Type 1 Diabetes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Teplizumab in Recent-Onset Type 1 Diabetes Clinical Trial page.